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INTRODUCTION
Amyloid precursor protein (APP) is a ubiquitously expressed type I transmembrane protein. It is implicated in pathogenic mechanisms leading to Alzheimer's Disease (AD) due to its known proteolytic processing via the amyloidogenic pathway to generate the neurotoxic amyloid-β peptides.
These amyloid-β peptides form the extracellular amyloid plaques, key pathological traits of AD. The function of APP itself is unclear, although evidence does support a role as a trophic factor promoting neurite outgrowth, neuronal migration and repair via interaction with extracellular matrix proteins (reviewed in Muller and Zheng, 2012; Hoe et al., 2012) . We recently proposed a new role for APP as a regulator of cell surface N-methyl-D-aspartate (NMDA) receptor homeostasis. This is because it was found that APP co-associated with the two major NMDA receptors expressed in adult brain, i.e. GluN1/GluN2A and GluN1/GluN2B, and indeed also GluN1/GluN2A/neuropilin tolloid-like 1 (Neto1) and GluN1/GluN2B/Neto1 complexes (Cousins et al., 2009; Innocent et al., 2012) .
Over-expression of APP resulted in an enhanced cell surface NMDA receptor expression. Similar findings were also reported by Hoe et al. (2009) , thus both groups surmised that APP may be an important contributor to the proper functioning of excitatory post-synaptic mechanisms. This may be
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particularly important for familial forms of early onset autosomal dominant AD where gene duplications of the APP gene have been identified (Cabrejo et al., 2006; McNaughton et al., 2012) .
APP is a member of a gene family that contains two other members, amyloid precursor proteins 1 and 2 (APLP1 and APLP2). The three proteins are highly homologous, sharing ~ 38 -51 % amino acid sequence identity (reviewed in Walsh et al., 2007; Ali et al., 2013) . APLP1 and APLP2 both undergo proteolytic processing similarly to APP; however, the amyloid-β sequence is not conserved between APP and APLP1 or APLP2. APLP2, similarly to APP, is ubiquitous and is expressed in neuronal and non-neuronal tissues, whereas APLP1 is found primarily in cells of the nervous system (Lorent et al., 1995) . The study of APP and APLP1/2 knock-out mice suggests functional differences between the three family members and, significantly, a particular importance for APLP2 in the physiology of the central nervous system (reviewed in Aydin et al., 2012) .
To gain further insight into the significance of APP/NMDA receptor interactions, it was of interest to investigate if APLP1 and APLP2 behaved similarly to APP with regard to their respective association and receptor cell surface trafficking. The results are reported in this paper.
EXPERIMENTAL PROCEDURES

Constructs and antibodies
The constructs, pCISGluN1-1a, pCISGluN2A, pCISGluN2B and pCI-neoAPP695 FLAG were as previously described (Cik, et al., 1993; Hawkins et al., 1999; Perkinton, et al., 2004) . Note that only the GluN1-1a splice variant was used thus pCISGluN1 and GluN1 are used throughout the manuscript to denote the GluNR1-1a splice variant. pCMV6APLP1 (variant 2, accession number NM_005166) and pCMV6APLP2 (variant 2 accession number NM_001142276) were purchased from OriGene (Rockville, Maryland, USA). Each clone generates APLP1 and APLP2 with a C-terminal c-Myc tag.
Accepted Article
Anti-GluN1 C2, anti-GluN2A (44-58), anti-GluN2A (1381-1394), anti-GluN2A/2B (raised against the amino acid sequence NR2A 1454-1464 but recognizes GluN2A and GluN2B), anti-GluN2B (46-60) and anti-APP (679-695) antibodies (all antibody amino acid sequences correspond to numbering for the respective immature proteins) were raised, generated and affinity-purified as previously described (Chazot, et al., 1992; Hawkins et al., 1999; Groc, et al., 2006; Cousins et al., 2009) . AntiGluN2B antibodies were from Millipore (Massachusetts, USA). Anti-His antibodies were from Life
Technologies Ltd (Paisley, Scotland). Anti-c-Myc clone 4A6 mouse monoclonal antibodies were from Upstate (Charlottesville, VA). Anti-APLP1 antibodies raised against human APLP1 200-300
and anti-APLP2 raised against human APLP2 262-491 were from AbCam (Cambridge, UK).
Mammalian cell transfections
Human embryonic kidney (HEK) 293 cells (purchased for the American Type Culture Collection (ATCC), Virginia, USA) were transfected using the calcium phosphate method as described (Cik et al., 1993) . For double transfections 10 µg DNA were used at a 1:1 ratio. For triple transfections a total of 20 µg DNA were used with a ratio of 1:3 GluN1: GluN2A or GluN1: GulN2B (10 µg total) with 10 µg APP695 FLAG , 10 µg APLP1 c-Myc or 10 µg APLP2 c-Myc
. HEK 293 cells expressing GluN1/GluN2 were cultured post-transfection in the presence of 1 mM ketamine to prevent cell cytotoxicity. Transfected cells were incubated for 24 h post-transfection and either assayed for cell surface NMDA receptor expression or they were harvested and used in immunoprecipitation assays.
Immunoprecipitation assays
Immunoprecipitations were carried out as previously described from HEK 293 transfected cells 
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with 1 % (w/v) sodium deoxycholate. Triton X-100 or sodium deoxycholate detergent extracts were centrifuged at 100,000 xg and the resultant supernatants used for the immunoprecipitations (Cousins et al., 2009) . Immunoprecipitating antibodies used were anti-GluN1 C2, anti-GluN2A (1381-1394) and anti-GluN2A/2B. The resulting immune pellets were analysed by SDS-PAGE followed by immunoblotting.
Immunoblotting
Immunoblotting was carried out using 7.5% (w/v) polyacrylamide slab minigels all as described previously (Papadakis et al., 2004) . Primary antibodies used were as follows: anti-GluN1 C2; anti- 
Determination of NMDA receptor cell surface expression by ELISA
The surface expression of GluN1/GluN2A and GluN1/GluN2B receptors was measured using antiGluN2A (44-58) and anti-GluN2B (46-60) antibodies respectively since for GluN1-1a-containing NMDA receptors, cell surface expression occurs when GluN1-1a is co-expressed with GluN2A or
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GluN2B receptor subunits (McIlhinney et al. 1998) . Cell surface ELISA was carried out as previously described (Papadakis et al., 2004; Cousins et al., 2008) .
Analysis of results
All results are the means ± SEM and were analysed by the Student's two tailed paired t test.
RESULTS AND DISCUSSION
APLP1 and APLP2 associate with GluN1/GluN2 NMDA receptors via association with GluN1 subunits APP is a member of a gene family which contains two other members, APLP1 and APLP2, that share significant, i.e. at least 57 %, amino acid sequence similarity. Thus to gain insight into the functional significance of APP/NMDA receptor association, the potential interaction of NMDA receptors with these other family members was investigated initially in a model heterologous expression system. In the first instance, the co-immunoprecipitation of APLP1 and APLP2 with GluN1, GluN2A and GluN2B single subunits was investigated. The results shown in Figure 1 reveal that similarly to APP695 FLAG , both APLP1 c-Myc (M r = 87 ± 1 kDa n =18) and APLP2 c-Myc (141 ± 3 kDa n =18) coimmunoprecipitate with GluN1 single subunits ( Figure 1A and 1D) but not with GluN2A ( Figure 1B and 1E) nor GluN2B ( Figure 1C and 1F) single subunits. Since when expressed alone, GluN1 is retained in the endoplasmic reticulum, this suggests that similarly to APP, APLP1 and APLP2 associate with GluN1 in this subcellular compartment.
To determine if APLP1 and APLP2 co-immunoprecipitate with assembled GluN1/GluN2 NMDA receptors, either GluN1/GluN2A or GluN1/GluN2B combinations were co-expressed with APLP1 
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This article is protected by copyright. All rights reserved. (Figure 2A and 2C) . Similarly, immunoprecipitation with anti-GluN2A/2B
antibodies to precipitate GluN2B subunits, results in the detection of GluN1 and APLP1 c-Myc or APLP2 C-Myc in the respective immune pellets ( Figure 2B and 2D ).
APLP1 and APLP2 associate with NMDA receptors in native brain tissues
The co-association of APLP1 and APLP2 with native NMDA receptors was also investigated.
However in order to do this, it was necessary to validate the specificity of anti-APLP1 and anti-APLP2 antibodies since each was raised against a respective fusion protein which had amino acid similarity with the other family members (see Methods). Thus APP695 FLAG , APLP1 c-Myc and APLP2 antibodies recognized APP M r = 103 kDa ± 2 (n = 3) but in addition, also both APLP1 and APLP2. This is not unexpected given the identity between the three isoforms at the respective C-termini.
However, the antibody is valid for the recognition of APP since the molecular sizes of APP, APLP1
and APLP2 are distinct ( Figure 3A ). Despite the fact that the three antibodies recognize immunoreactive species with distinct molecular weights in immunoblots, there is a caveat to be aware of in that in the co-immunoprecipitation assays, the antibodies are targeting native, i.e. folded APLP1, APLP2 and APP. Thus there is still a possibility of cross-immunoreactivity between the three antibodies. Ultimately, the optimum control for the specificity of these antibodies would be the use of the appropriate knock-out mice.
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Immunoprecipitations from detergent extracts of adult rat brain were carried out using anti-GluN1 C2
antibodies and immune pellets were analysed for GluN1 immunoreactivity to prove that the immunoprecipitation was successful; for GluN2A and GluN2B immunoreactivities to demonstrate the pelleting of an assembled GluN1/GluN2 NMDA receptor and, anti-APP, anti-APLP1 and anti-APLP2
antibodies to determine possible co-immunoprecipitation with APP family members. It was found that GluN1 was always immunoprecipitated as was GluN2A and GluN2B (Figure 3) . Furthermore, APP, APLP1 and APLP2 were also all co-immunopreicpitated by anti-GluN1 C2 antibodies (Figure 3 ). The immunoreactive bands were strongest for APP and APLP1. It was difficult to detect APLP2 in detergent extracts reflecting a low level of APLP2 expression in adult brain. Nevertheless, a clear immunoreactive species was found in anti-GluN1 C2 immunoprecipitates. As always, control nonimmune Ig was used as a negative control and no APP, APLP1 nor APLP2 immunoreactivities were found in these samples (Figure 3 ).
APLP1 and APLP2 enhance GluN1/GluN2A and GluN1/GluN2B NMDA receptor cell surface expression with no concomitant change in receptor subunits
In addition to interacting with NMDA receptors, we and others (Hoe et al., 2009) showed that APP enhanced the cell surface expression of NMDA receptors. To determine if this was the case for APLP1 and APLP2, GluN1/GluN2A and GluN1/GluN2B NMDA receptors were co-expressed in parallel with either APLP1, APLP2 and with APP as a positive control and cell surface NMDA receptor expression was measured by ELISA 24 h post-transfection. Similarly to APP, APLP1 and APLP2 both enhanced GluN1/GluN2A and GluN1/GluN2B cell surface receptor expression. There was no significant difference in the fold enhancement when APP was compared to that elicited by APLP1 and APLP2 i.e. for each, an approximate two-fold increase in cell surface expression was observed (Figure 4) . Again, similarly to APP the increase in cell surface expression was not accompanied by any observed change in the total expression of GluN1, GluN2A or GluN2B subunits (Figure 4 ).
Concluding remarks
The function of APP is unknown, although new insights into its functional significance have recently been gained through the discovery that it contributes to the regulation of surface expression of NMDA receptors (Hoe et al., 2009; Cousins et al., 2009) . Since APP is a member of a gene family that contains two other members, it is important to ascertain if the related APP proteins possess the same properties as APP with respect to their interactions with NMDA receptors. Any observed differences or similarities would thus yield further insight into APP/NMDA receptor protein/protein interactions.
In summary, both APLP1 and APLP2 behaved similarly to APP in that they both coimmunoprecipitated with the two major NMDA receptor subtypes, GluN1/GluN2A and GluN1/GluN2B, via interaction with the obligatory GluN1 subunit. Furthermore, APLP1 and APLP2 both enhanced GluN1/GluN2A and GluN1/GluN2B cell surface expression to fold-increases that are similar to those induced by APP.
Thus no differences were apparent in the interactions between NMDA receptors and APP, APLP1 and APLP2. A caveat to this however, is that it is known that all three members can form both homo-and hetero-oligomers (Kaden et al., 2012) . Since HEK 293 cells express endogenous APP, it cannot be excluded that either APLP1 and/or APLP2 form heteroligomers with APP and that APLP1 and/or APLP2 are found in immune pellets by virtue of the interaction of APP with GluN1. However, in the immunoprecipitations from native brain tissue, single immunoreactive species are detected by anti-APP, anti-APLP1 and anti-APLP2 antibodies. Because each has a distinct molecular weight ( Figure   4 ), co-immunoprecipitation due to hetero-oligomerisation is unlikely. It is still unclear if the association between APP and NMDA receptors is direct or mediated via an intermediary protein.
Whichever is the case, the findings reported here show that the protein binding domain responsible for the association must be conserved between the three family members. It is also unclear why the APP/NMDA receptor interaction, be it direct or indirect, results in an enhanced surface expression. Hoe et al. (2009) suggested that APP enhanced GluN2B-containing NMDA receptors by decreasing
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receptor internalization, but the mechanism by which this occurs remains elusive. Our findings differ in that APP does not distinguish between GluN1/GluN2A and GluN1/GluN2B since the surface expression of both is enhanced by APP, but, again, the mechanism is yet to be resolved. Further studies are necessary to gain more insight into the role of the APP family in the regulation of cell surface NMDA receptor homeostasis and the possible relationship to Alzheimer's disease. 
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